Philip Mease

Summary

Affiliation: Seattle Rheumatology Associates
Country: USA

Publications

  1. ncbi request reprint Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Curr Opin Rheumatol 15:205-12. 2003
  2. ncbi request reprint Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Am Acad Dermatol 54:685-704. 2006
  3. ncbi request reprint Fibromyalgia syndrome
    Philip Mease
    Seattle Rhumatology Associates, Seattle, WA 98104, USA
    J Rheumatol 34:1415-25. 2007
  4. ncbi request reprint Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    J Rheumatol 35:20-30. 2008
  5. doi request reprint Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises
    Phillip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Arthritis Rheum 59:952-60. 2008
  6. pmc Adalimumab in the treatment of arthritis
    Philip J Mease
    Seattle Rheumatology Associates Seattle, WA, USA
    Ther Clin Risk Manag 3:133-48. 2007
  7. doi request reprint Evaluation of duloxetine for chronic pain conditions
    Philip J Mease
    Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    Pain Manag 1:159-70. 2011
  8. doi request reprint A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
    P Mease
    Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, Washington, USA
    Ann Rheum Dis 71:1183-9. 2012
  9. doi request reprint Pharmacotherapy of fibromyalgia
    Philip J Mease
    Rheumatology Research, Swedish Medical Center, Seattle, WA, USA
    Best Pract Res Clin Rheumatol 25:285-97. 2011
  10. doi request reprint Distinguishing inflammatory from noninflammatory arthritis, enthesitis, and dactylitis in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting
    Philip J Mease
    Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, USA
    J Rheumatol 39:415-7. 2012

Detail Information

Publications71

  1. ncbi request reprint Disease-modifying antirheumatic drug therapy for spondyloarthropathies: advances in treatment
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Curr Opin Rheumatol 15:205-12. 2003
    ..This article reviews recent progress in disease-modifying therapy for spondyloarthropathy, including new biologic response modifiers, such as the tumor necrosis factor-alpha inhibitors etanercept and infliximab...
  2. ncbi request reprint Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Am Acad Dermatol 54:685-704. 2006
    ....
  3. ncbi request reprint Fibromyalgia syndrome
    Philip Mease
    Seattle Rhumatology Associates, Seattle, WA 98104, USA
    J Rheumatol 34:1415-25. 2007
    ..The OMERACT process has provided a framework for identification of key domains to be assessed and a path toward validation and standardization of outcome measures for clinical trials in FM...
  4. ncbi request reprint Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    J Rheumatol 35:20-30. 2008
    ....
  5. doi request reprint Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises
    Phillip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Arthritis Rheum 59:952-60. 2008
    ....
  6. pmc Adalimumab in the treatment of arthritis
    Philip J Mease
    Seattle Rheumatology Associates Seattle, WA, USA
    Ther Clin Risk Manag 3:133-48. 2007
    ..The safety profile was similar to other TNF antagonists. Inhibition of TNF activity by adalimumab also significantly improved physical functioning and quality of life measures...
  7. doi request reprint Evaluation of duloxetine for chronic pain conditions
    Philip J Mease
    Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, USA Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    Pain Manag 1:159-70. 2011
    ..Treatment-emergent adverse events are generally mild to moderate in severity, and tend to occur early and transiently. ..
  8. doi request reprint A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
    P Mease
    Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, Washington, USA
    Ann Rheum Dis 71:1183-9. 2012
    ..Interleukin 6 (IL-6) plays a key role in the inflammatory cascade in rheumatoid arthritis. BMS945429 is a humanised, monoclonal antibody that potently binds IL-6...
  9. doi request reprint Pharmacotherapy of fibromyalgia
    Philip J Mease
    Rheumatology Research, Swedish Medical Center, Seattle, WA, USA
    Best Pract Res Clin Rheumatol 25:285-97. 2011
    ..Current therapies neither completely treat FM symptoms nor benefit all patients; thus, further research on new therapies with different mechanisms and side-effect profiles is needed...
  10. doi request reprint Distinguishing inflammatory from noninflammatory arthritis, enthesitis, and dactylitis in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting
    Philip J Mease
    Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, USA
    J Rheumatol 39:415-7. 2012
    ....
  11. doi request reprint Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington 98104, USA
    J Rheumatol 39:391-3. 2012
    ..Introductions to the discussions at the GRAPPA 2010 meeting are included in this prologue...
  12. pmc Fatigue in fibromyalgia: a conceptual model informed by patient interviews
    Louise Humphrey
    Mapi Values, Adelphi Mill, Bollington, Macclesfield Cheshire SK10 5JB, UK
    BMC Musculoskelet Disord 11:216. 2010
    ..The data obtained informed the development of a conceptual model of fatigue in FM...
  13. pmc Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
    ..The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA)...
  14. pmc Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
    Dafna D Gladman
    University of Toronto, 399 Bathurst Street, Room 1E 410B, Toronto, Ontario M5T 2S8, Canada
    Arthritis Res Ther 12:R113. 2010
    ..To identify independent predictors of radiographic progression in psoriatic arthritis (PsA) for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial (ADEPT)...
  15. doi request reprint Psoriatic arthritis assessment and treatment update
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington, USA
    Curr Opin Rheumatol 21:348-55. 2009
    ..To review the current state of knowledge about assessment and management of psoriatic arthritis (PsA)...
  16. doi request reprint Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington, USA
    Am J Med 122:S44-55. 2009
    ..Pharmacologic agents that specifically target serotonin and norepinephrine reuptake may prove to be valuable tools in the treatment of fibromyalgia...
  17. doi request reprint Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Wahington 98104, USA
    J Rheumatol 37:692-703. 2010
    ....
  18. doi request reprint Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study
    Philip J Mease
    Seattle Rheumatology Associates, Division of Rheumatology Research, Swedish Medical Center, Seattle, Washington, USA
    J Am Acad Dermatol 60:402-11. 2009
    ..A single course of alefacept intramuscularly in combination with methotrexate (MTX) was effective in treating both psoriasis and psoriatic arthritis (PsA)...
  19. doi request reprint Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104, USA
    J Rheumatol 37:917-27. 2010
    ..To assess the efficacy and safety of 1 versus 2 courses of rituximab over 48 weeks in patients with rheumatoid arthritis (RA)...
  20. doi request reprint Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates and Swedish Medical Center, 1101 Madison Street, Seattle, WA 98104, USA
    J Rheumatol 37:1221-7. 2010
    ..To evaluate the effects of etanercept treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA)...
  21. ncbi request reprint Spondyloarthritis update: new insights regarding classifcation, pathophysiology, and management
    Philip J Mease
    University of Washington School of Medicine, Seattle, Washington, USA
    Bull NYU Hosp Jt Dis 66:203-9. 2008
    ..International treatment recommendations have been or are being developed based on the evidence base from clinical trials...
  22. doi request reprint Psoriatic arthritis: pharmacotherapy update
    Philip J Mease
    Swedish Medical Center, Division of Rheumatology Research, Seattle Rheumatology Associates, University of Washington, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    Curr Rheumatol Rep 12:272-80. 2010
    ....
  23. doi request reprint Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial
    Philip Mease
    University of Washington, Seattle, WA, USA
    Arthritis Rheum 63:939-48. 2011
    ..To assess the safety and efficacy of abatacept, a selective T cell costimulation modulator, in patients with psoriatic arthritis (PsA)...
  24. doi request reprint Improving the routine management of rheumatoid arthritis: the value of tight control
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 37:1570-8. 2010
    ..A case study clearly demonstrates the benefits of the tight control approach in routine clinical practice...
  25. doi request reprint Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, WA 98104, USA
    J Rheumatol 38:2461-5. 2011
    ..To evaluate changes in function as measured by Health Assessment Questionnaire Disability Index (HAQ-DI) and the meaningfulness of the changes, in importance and satisfaction, in patients with psoriatic arthritis (PsA)...
  26. pmc Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update
    Philip J Mease
    Division of Rheumatology Research, Swedish Medical Center, University of Washington, Seattle, Washington, USA
    J Rheumatol 38:1487-95. 2011
    ..Final results of this work will be published in a separate report pending completion of analyses...
  27. ncbi request reprint The potential roles for novel biomarkers in rheumatoid arthritis assessment
    P J Mease
    Rheumatology Research, Swedish Medical Center, Seattle, WA 98104, USA
    Clin Exp Rheumatol 29:567-74. 2011
    ..This article reviews the current management strategies for monitoring RA and the potential impact that multi-biomarker assays may have on RA assessment, which may further improve clinical outcomes...
  28. doi request reprint Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    J Rheumatol 38:1546-51. 2011
    ..Evidence is presented for the efficacy of centrally acting analgesics for OA pain (opioids, antiepileptics, tricyclic antidepressants, and serotonin/norepinephrine receptor inhibitors)...
  29. ncbi request reprint Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial
    Philip Mease
    Swedish Medical Center and University of Washington, Seattle, Washington
    Arthritis Rheum 63:939-48. 2011
    ..To assess the safety and efficacy of abatacept, a selective T cell costimulation modulator, in patients with psoriatic arthritis (PsA)...
  30. doi request reprint Inflammatory musculoskeletal disease: identification and assessment
    Philip J Mease
    Swedish Medical Center and University of Washington, Seattle, WA 98104, USA
    J Rheumatol 38:557-61. 2011
    ..Features that assist identification and assessment of PsA are reviewed in this article...
  31. doi request reprint Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
    Philip J Mease
    University of Washington, Seattle, WA 98104, USA
    J Rheumatol 38:522-5. 2011
    ..Other topics for discussion at the GRAPPA meeting included presentations on genetic associations with PsA and on comorbidities in patients with PsA. Current and future research projects also were outlined...
  32. doi request reprint Psoriatic arthritis: update on pathophysiology, assessment and management
    Philip J Mease
    Seattle Rheumatology Associates, 1101 Madison St Ste 1000, Seattle, WA 98104, USA
    Ann Rheum Dis 70:i77-84. 2011
    ..Although there is considerable overlap with RA, there are some differences in pathophysiology and approach to assessment and management that are important to consider. This paper reviews these subjects, with an emphasis on recent data...
  33. ncbi request reprint Psoriatic arthritis - update on pathophysiology, assessment, and management
    Philip J Mease
    University of Washington School of Medicine, Seattle, Washington 98104, USA
    Bull NYU Hosp Jt Dis 68:191-8. 2010
    ..A number of advances in assessment and treatment have occurred in the last few years, which are highlighted in this update. This article reviews assessment and treatment of PsA, with an emphasis on recent data...
  34. pmc Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    Rheumatology (Oxford) 50:261-70. 2011
    ..CZP was generally well tolerated when used either as monotherapy or added to MTX; most adverse events were mild or moderate. Taken together, the results of these trials suggest that CZP is an effective new option for the treatment of RA...
  35. pmc Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
    P J Mease
    Swedish Medical Center and University of Washington, Seattle, Washington, USA
    Ann Rheum Dis 68:702-9. 2009
    ..To evaluate the long-term effectiveness and tolerability of adalimumab in the treatment of psoriatic arthritis (PsA)...
  36. ncbi request reprint Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study
    Philip J Mease
    Swedish Medical Center, Seattle, Washington, USA
    Arthritis Rheum 54:1638-45. 2006
    ..To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA)...
  37. ncbi request reprint Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 33:712-21. 2006
    ..Clinical and radiographic responses were evaluated in patients with psoriatic arthritis (PsA) treated for up to 2 years with etanercept...
  38. ncbi request reprint Fibromyalgia syndrome
    Philip J Mease
    Swedish Medical Center, The University of Washington School of Medicine, Seattle, WA, USA
    J Rheumatol 32:2270-7. 2005
    ..A prioritized list of domains of FM to be investigated was thus developed, key issues and controversies in the field were debated, and consensus on a research agenda on outcome measure development was reached...
  39. ncbi request reprint Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    Expert Opin Biol Ther 5:1491-504. 2005
    ..In addition, structural changes were inhibited, and statistically and clinically significant improvements in measures of disability and quality of life were observed. Adalimumab was generally safe and well tolerated...
  40. ncbi request reprint Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, Washington 98104, USA
    Arthritis Rheum 52:3279-89. 2005
    ..Adalimumab, a fully human, anti-tumor necrosis factor monoclonal antibody, was evaluated for its safety and efficacy compared with placebo in the treatment of active psoriatic arthritis (PsA)...
  41. ncbi request reprint Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment
    Philip Mease
    Seattle Rheumatology Associates, Washington 98104, USA
    J Rheumatol Suppl 75:6-21. 2005
    ..The multifaceted nature of FM suggests that multimodal individualized treatment programs may be necessary to achieve optimal outcomes in patients with this syndrome...
  42. ncbi request reprint Psoriatic arthritis therapy advances
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Rheumatology Research Division, and University of Washington School of Medicine Seattle, Washington 98104, USA
    Curr Opin Rheumatol 17:426-32. 2005
    ..This paper will review the data published in 2004 on the treatment of psoriatic arthritis, which arthritis affects 6 to 39% of all patients with psoriasis...
  43. pmc Psoriatic arthritis treatment: biological response modifiers
    P J Mease
    Seattle Rheumatology Associates, 1101 Madison St, 10th Floor, Seattle, WA 98104, USA
    Ann Rheum Dis 64:ii78-82. 2005
    ..Also, it will be useful to learn more about the effects of combining traditional disease modifying drugs and the newer biologicals...
  44. pmc Psoriatic arthritis assessment tools in clinical trials
    P J Mease
    Seattle Rheumatology Associates and Swedish Medical Center Rhematology Research Division, University of Washington School of Medicine, Seattle, WA 98104, USA
    Ann Rheum Dis 64:ii49-54. 2005
    ..This report reviews the current state of the art of assessment in PsA and points toward future directions of development of this field...
  45. ncbi request reprint Diagnosis and treatment of psoriatic arthritis
    Philip Mease
    Seattle Rheumatology Associates, Swedish Hospital Medical Center, Division of Clinical Research, WA 98104, USA
    J Am Acad Dermatol 52:1-19. 2005
    ..This article reviews the diagnostic and treatment challenges of psoriatic arthritis as they relate to pathogenesis and burden of disease...
  46. ncbi request reprint Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Arthritis Rheum 50:2264-72. 2004
    ..In this study, we further evaluated the safety, efficacy, and effect on radiographic progression of etanercept in patients with PsA...
  47. ncbi request reprint Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept
    Phillip J Mease
    Seattle Rheumatology Associates, 1101 Madison, Suite 230, Seattle, WA 98104, USA
    J Rheumatol 31:1356-61. 2004
    ..Immune system function can be assessed by evaluating response to vaccination. We assessed the ability of patients with PsA treated with etanercept to produce antibodies in response to pneumococcal antigen challenge...
  48. pmc TNFalpha therapy in psoriatic arthritis and psoriasis
    P Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA
    Ann Rheum Dis 63:755-8. 2004
  49. ncbi request reprint Current treatment of psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Division of Clinical Research, Swedish Hospital Medical Center, University of Washington School of Medicine, Seattle, WA, USA
    Rheum Dis Clin North Am 29:495-511. 2003
    ....
  50. ncbi request reprint Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology
    Philip Mease
    Seattle Rheumatology Associates, Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    Curr Rheumatol Rep 8:348-54. 2006
    ....
  51. ncbi request reprint B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 35:1245-55. 2008
    ..In this review we explore the rationale behind B cell-targeted therapy, highlight the results of clinical trials with rituximab in RA and other autoimmune diseases, and describe other emerging therapies directed at B cells...
  52. ncbi request reprint Assessment tools in psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 35:1426-30. 2008
    ..We present a review of those discussions...
  53. doi request reprint Assessing the impact of psoriatic arthritis on patient function and quality of life: lessons learned from other rheumatologic conditions
    Philip J Mease
    Seattle Rheumatology Associates, Rheumatology Clinical Research, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, USA
    Semin Arthritis Rheum 38:320-35. 2009
    ..To identify and describe measures that can be used to assess the impact of psoriatic arthritis (PsA) on patient functioning and health-related quality of life (HRQOL)...
  54. ncbi request reprint A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Rheumatol 35:502-14. 2008
    ..To evaluate the efficacy and safety of pregabalin for symptomatic relief of pain associated with fibromyalgia (FM) and for management of FM...
  55. ncbi request reprint Current treatment for psoriatic arthritis and other spondyloarthritides
    Philip Mease
    Division of Rheumatology Research, Swedish Medical Center
    Rheum Dis Clin North Am 32:11-20. 2006
  56. pmc Fibromyalgia syndrome module at OMERACT 9: domain construct
    Philip Mease
    Seattle Rheumatology Associates and Division of Rheumatology Research, Swedish Medical Center, Seattle, WA 98104, USA
    J Rheumatol 36:2318-29. 2009
    ..In conclusion, a multidimensional symptom core set is proposed for evaluation of FM in clinical trials. Research on improved measures of single domains and composite measures is ongoing...
  57. doi request reprint Single-joint outcome measures: preliminary validation of patient-reported outcomes and physical examination
    Alison E Heald
    Targeted Genetics Corporation, Seattle, Washington, USA
    J Rheumatol 37:1042-8. 2010
    ..To assess the validity, responsiveness, and reliability of single-joint outcome measures for determining target joint (TJ) response in patients with inflammatory arthritis...
  58. ncbi request reprint Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis?
    Philip Mease
    Rheumatology Research, Swedish Medical Center Clinical Professor University of Washington School of Medicine, Seattle, USA
    Clin Exp Rheumatol 31:S59-62. 2013
    ..A controlled dose-reduction and discontinuation study design is outlined, which may provide controlled evidence for such a paradigm of treatment. ..
  59. doi request reprint Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA, USA
    Semin Arthritis Rheum 39:454-64. 2010
    ..To assess the long-term safety, tolerability, and efficacy of duloxetine in patients with fibromyalgia...
  60. doi request reprint The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial
    Philip J Mease
    Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104, USA
    J Rheumatol 36:398-409. 2009
    ..To evaluate the safety and efficacy of milnacipran, a dual norepinephrine and serotonin reuptake inhibitor, in the treatment of fibromyalgia (FM)...
  61. doi request reprint Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, WA 98104, USA pmease nwlink com
    Dermatology 220:1-7. 2010
    ..Psoriatic arthritis often affects patients with psoriasis...
  62. ncbi request reprint Recent advances in the management of psoriatic arthritis
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    Curr Opin Rheumatol 16:366-70. 2004
    ..Newer trials in psoriatic arthritis therapy demonstrate ongoing ability to control disease symptoms and signs and the progression of the disease significantly...
  63. doi request reprint Pharmacotherapy of fibromyalgia
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104
    Rheum Dis Clin North Am 35:359-72. 2009
    ....
  64. ncbi request reprint Update on treatment of psoriatic arthritis
    Philip Mease
    Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122, USA
    Bull NYU Hosp Jt Dis 70:167-71. 2012
    ..Anti-TNF therapies remain the gold standard of effectiveness. New therapeutic options are potentially emerging including ustekinumab, abatacept, several IL-17 inhibitors, apremilast, JAK inhibitors, and possibly IL-6 inhibitors...
  65. doi request reprint Psoriatic arthritis and spondyloarthritis assessment and management update
    Philip Mease
    Swedish Medical Center, Seattle WA, USA
    Curr Opin Rheumatol 25:287-96. 2013
    ....
  66. ncbi request reprint Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?
    Philip J Mease
    Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104, USA
    Curr Pain Headache Rep 12:399-405. 2008
    ..Trials are currently being developed to assess the potential additive or synergistic effects of combined central pharmacotherapy and to assess the safety and tolerability of this approach...
  67. ncbi request reprint Psoriatic arthritis update
    Philip Mease
    Seattle Rheumatology Associates, Swedish Medical Center, University of Washington School of Medicine, Seattle, Washington, USA
    Bull NYU Hosp Jt Dis 64:25-31. 2006
    ..Adverse effects with these agents can be significant but are usually manageable. Cost is also significant, but cost-effectiveness analysis is demonstrating reasonable trade-off between cost and benefit...
  68. doi request reprint Nursing considerations for infusion therapy in rheumatoid arthritis versus malignancy
    Nicole Furfaro
    Seattle Rheumatology Associates, Seattle, Washington 98104, USA
    J Infus Nurs 31:350-60. 2008
    ..This article focuses on the specific pathophysiology of the RA disease state and patient characteristics that may affect infusion therapy, illustrated by a case study...
  69. ncbi request reprint Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy
    Philip J Mease
    Seattle Rheumatology Associates, Seattle, Washington, USA
    J Rheumatol 32:616-21. 2005
    ..To assess the effects of treatment with prasterone (dehydroepiandrosterone) on bone mineral density (BMD) in female patients with mild to moderate systemic lupus erythematosus (SLE) receiving chronic treatment with glucocorticoids...
  70. doi request reprint Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial
    Mario H Cardiel
    Hospital General Dr Miguel Silva, Morelia, Michoacan, Mexico
    Arthritis Rheum 58:2470-80. 2008
    ....